The shadow of generic competition has long loomed around copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the prospects of related medicinal ventures. While initial years saw substantial profits, the intellectual property lapse has opened the door for less expensive copies, potentially diminishing profitability and present